Keywords

Diabetes innovation, diabetes technology, insulin pump therapy, multiple daily injections, type 2 diabetes

 

Authors

  1. Stallings, Dana E. DNP, FNP-C, CDCES, BC-ADM (Owner & Nurse Practitioner)

ABSTRACT

Background: More than 35 million Americans live with type 2 diabetes (T2D), resulting in the need for newer strategies and technologies to manage the disease. Insulin pump therapy (IPT) has historically been reserved for type 1 diabetes, although emerging data demonstrates improved glucose outcomes for patients with T2D using IPT.

 

Purpose: To measure the change in HgbA1c in patients with T2D after changing therapy from multiple daily injections (MDI) to continuous subcutaneous insulin infusion through IPT.

 

Methodology: A retrospective comparison study was conducted by reviewing the electronic medical record of patients with T2D, older than 18 years, who had been on multiple daily insulin injections for at least 1 year, followed by IPT for at least 1 year.

 

Results: One hundred seventy-one patients met the inclusion criteria. There was a statistically significant reduction in mean HgbA1c from 9.6% to 7.6%.

 

Conclusion: Insulin pump therapy may result in lower HgbA1c levels for T2D not at goal on MDI.

 

Implications: Patients on multiple daily insulin injections who are not at goal should be considered for IPT.